{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:18:48Z","timestamp":1794907128204,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Osteoarthritis (OA) is the commonest form of inflammatory joint disease. Unfortunately, to date, there is no appropriate treatment for OA.\n                      <jats:italic>Boswellia serrata<\/jats:italic>\n                      was considered as a potent anti-inflammatory, anti-arthritic and analgesic agent that may be a drug for OA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this meta-analysis, data from randomized controlled trials were obtained to assess the effects of Boswellia or its extract versus placebo or western medicine in patients with OA. The primary outcomes included visual analogue score (VAS), WOMAC pain, WOMAC stiffness, WOMAC function and lequesne index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      Seven trials involving 545 patients were included. Compared with the control group, Boswellia and its extract may relieve the pain [VAS: (WMD -8.33; 95% CI -11.19, \u2212\u20095.46;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.00001); WOMAC pain: (WMD -14.22; 95% CI -22.34, \u2212\u20096.09; P\u2009=\u20090. 0006)] and stiffness [WOMAC stiffness: (WMD -10.04; 95% CI -15.86, \u2212\u20094.22; P\u2009=\u20090. 0007)], and improve the joint\u2019s function [WOMAC function: (WMD -10.75; 95% CI -15.06, \u2212\u20096.43;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0. 00001); lequesne index: (WMD -2.27; 95% CI -3.08, \u2212\u20091.45;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0. 00001)].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on current evidence, Boswellia and its extract may be an effective and safe treatment option for patient with OA, and the recommended duration of treatment with Boswellia and its extract is at least 4\u2009weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12906-020-02985-6","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:26:01Z","timestamp":1594981561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9327-5385","authenticated-orcid":false,"given":"Ganpeng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"2985_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0033-8389(03)00161-1","volume":"42","author":"DT Felson","year":"2004","unstructured":"Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin N Am. 2004;42:1\u20139.","journal-title":"Radiol Clin N Am"},{"key":"2985_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7326\/0003-4819-133-8-200010170-00016","volume":"133","author":"DT Felson","year":"2000","unstructured":"Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635\u201346.","journal-title":"Ann Intern Med"},{"key":"2985_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/bmj.321.7266.936","volume":"321","author":"WB Karen","year":"2000","unstructured":"Karen WB, Javaid K, Arden N, et al. Regular review: medical management of osteoarthritis. BMJ. 2000;321:936\u201340.","journal-title":"BMJ."},{"issue":"8","key":"2985_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41584-019-0243-5","volume":"15","author":"A Beringer","year":"2019","unstructured":"Beringer A, Miossec P. Systemic effects of IL-17 in inflammatory arthritis. Nat Rev Rheumatol. 2019;15(8):491\u2013501. https:\/\/doi.org\/10.1038\/s41584-019-0243-5.","journal-title":"Nat Rev Rheumatol"},{"key":"2985_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/art.1780381104","volume":"38","author":"MC Hochberg","year":"1995","unstructured":"Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541\u20136. https:\/\/doi.org\/10.1002\/art.1780381104.","journal-title":"Arthritis Rheum"},{"key":"2985_CR6","doi-asserted-by":"crossref","unstructured":"Anonymous. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update: American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000; 43: 1905\u20131915.","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P"},{"key":"2985_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.59.12.936","volume":"59","author":"A Pendleton","year":"2000","unstructured":"Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of osteoarthritis: report of task force standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis. 2000;59:936\u201344. https:\/\/doi.org\/10.1136\/ard.59.12.936.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR8","doi-asserted-by":"publisher","first-page":"31S","DOI":"10.1016\/S0002-9343(98)00072-2","volume":"105","author":"G Singh","year":"1998","unstructured":"Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105:31S\u20138S.","journal-title":"Am J Med"},{"key":"2985_CR9","doi-asserted-by":"publisher","first-page":"23S","DOI":"10.1016\/S0002-9343(97)00207-6","volume":"104","author":"MR Griffin","year":"1998","unstructured":"Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug associated gastrointestinal injury. Am J Med. 1998;104:23S\u20139S.","journal-title":"Am J Med"},{"key":"2985_CR10","first-page":"1131","volume":"167","author":"JM Wright","year":"2002","unstructured":"Wright JM. Double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002;167:1131\u20137.","journal-title":"CMAJ."},{"key":"2985_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/BF01965005","volume":"18","author":"GB Singh","year":"1986","unstructured":"Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions. 1986;18:407\u201341.","journal-title":"Agents Actions"},{"key":"2985_CR12","first-page":"63","volume":"4","author":"B Ethan","year":"2004","unstructured":"Ethan B, Heather B, Theresa DH, Ivo F, Sadaf H, Jens H, David S, Catherine U. Boswellia. An evidence-based systematic review by the natural standard research collaboration. J Herbal Pharmacother. 2004;4:63\u201383.","journal-title":"J Herbal Pharmacother"},{"key":"2985_CR13","first-page":"1143","volume":"26","author":"H Safayhi","year":"1992","unstructured":"Safayhi H, Mack T, Sabieraj J, et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992;26:1143\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"2985_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1476-5381.1996.tb15235.x","volume":"117","author":"ER Sailer","year":"1996","unstructured":"Sailer ER, Subramanian LR, Rall B, et al. Acetyl-11-keto-\u03b2-boswellic acid (AKBA): structure requirements or binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol. 1996;117:615\u20138.","journal-title":"Br J Pharmacol"},{"key":"2985_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1078\/094471103321648593","volume":"10","author":"N Kimmatkar","year":"2003","unstructured":"Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine. 2003;10:3\u20137.","journal-title":"Phytomedicine."},{"key":"2985_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4103\/0974-8520.159007","volume":"35","author":"PK Perera","year":"2014","unstructured":"Perera PK, Perera M, Kumarasinghe N. Effect of Sri Lankan traditional medicine and Ayurveda on Sandhigata Vata (osteoarthritis of knee joint). Ayu. 2014;35:411\u20135. https:\/\/doi.org\/10.4103\/0974-8520.159007.","journal-title":"Ayu"},{"key":"2985_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4103\/0974-8520.72399","volume":"31","author":"MR Shah","year":"2010","unstructured":"Shah MR, Mehta CS, Shukla VD, et al. A Clinical study of Matra Vasti and an ayurvedic indigenous compound drug in the management of Sandhigatavata (Osteoarthritis). Ayu. 2010;31:210\u20137. https:\/\/doi.org\/10.4103\/0974-8520.72399.","journal-title":"Ayu"},{"key":"2985_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.4103\/0974-8520.96119","volume":"32","author":"PK Gupta","year":"2011","unstructured":"Gupta PK, Samarakoon SM, Chandola HM, et al. Clinical evaluation of Boswellia serrata (Shallaki) resin in the management of Sandhivata (osteoarthritis). Ayu. 2011;32:478\u201382. https:\/\/doi.org\/10.4103\/0974-8520.96119.","journal-title":"Ayu"},{"key":"2985_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1089\/dna.2005.24.244","volume":"24","author":"S Roy","year":"2005","unstructured":"Roy S, Khanna S, Shah H, et al. Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells. DNA Cell Biol. 2005;24:244\u201355. https:\/\/doi.org\/10.1089\/dna.2005.24.244.","journal-title":"DNA Cell Biol"},{"key":"2985_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4049\/jimmunol.174.1.498","volume":"174","author":"T Syrovets","year":"2005","unstructured":"Syrovets T, Buchele B, Krauss C, et al. Acetyl-boswellic acids inhibit lipopolysaccharide mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinases. J Immunol. 2005;174:498\u2013506.","journal-title":"J Immunol"},{"key":"2985_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/ars.2006.8.653","volume":"3","author":"S Roy","year":"2006","unstructured":"Roy S, Khanna S, Krishnaraju AV, et al. Regulation of vascular responses to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to anti-inflammatory Boswellia. Antioxid Redox Signal. 2006;3:653\u201360.","journal-title":"Antioxid Redox Signal"},{"key":"2985_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1745-4522.2009.01150.x","volume":"16","author":"K Sengupta","year":"2009","unstructured":"Sengupta K, Golakoti T, Marasetti A, et al. 30% 3-O-acetyl-11-keto-\u03b2-boswellic acid inhibits TNF\u03b1 production and blocks MAPK\/NF\u03baB activation in lipopolysaccharide induced THP-1 human monocytes. J Food Lipids. 2009;16:325\u201344.","journal-title":"J Food Lipids"},{"key":"2985_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3109\/15376516.2010.497978","volume":"20","author":"AV Krishnaraju","year":"2010","unstructured":"Krishnaraju AV, Sundararaju D, Vamsikrishna U, et al. Safety and toxicological evaluation of Aflapin: a novel Boswellia-derived anti-inflammatory product. Toxicol Mech Methods. 2010;20:556\u201363.","journal-title":"Toxicol Mech Methods"},{"key":"2985_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.7150\/ijms.7.366","volume":"7","author":"K Sengupta","year":"2010","unstructured":"Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin\u00ae and Aflapin\u00ae against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7:366\u201377.","journal-title":"Int J Med Sci"},{"key":"2985_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/15376520600620232","volume":"16","author":"K Lalithakumari","year":"2006","unstructured":"Lalithakumari K, Krishnaraju AV, Sengupta K, et al. Safety and toxicological evaluation of a novel, standardized 3-O-acetyl-11-keto-\u03b2-boswellic acid (AKBA)-enriched Boswellia serrata extract (5-Loxin). Toxicol Mech Methods. 2006;16:199\u2013226. https:\/\/doi.org\/10.1080\/15376520600620232.","journal-title":"Toxicol Mech Methods"},{"key":"2985_CR26","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1186\/ar2461","volume":"10","author":"K Sengupta","year":"2008","unstructured":"Sengupta K, Krishnaraju AV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10:R85.","journal-title":"Arthritis Res Ther"},{"key":"2985_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.intimp.2006.12.003","volume":"7","author":"B Gayathri","year":"2007","unstructured":"Gayathri B, Manjula N, Vinaykumar KS, et al. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNF\u03b1, IL-1\u03b2, NO and MAP kinases. Int Immunopharmacol. 2007;7:473\u201382.","journal-title":"Int Immunopharmacol"},{"key":"2985_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/bjsports-2016-097333","volume":"52","author":"X Liu","year":"2018","unstructured":"Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52:167\u201375. https:\/\/doi.org\/10.1136\/bjsports-2016-097333.","journal-title":"Br J Sports Med"},{"key":"2985_CR29","doi-asserted-by":"publisher","first-page":"CD002947","DOI":"10.1002\/14651858.CD002947.pub2","volume":"22","author":"M Cameron","year":"2014","unstructured":"Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014;22:CD002947. https:\/\/doi.org\/10.1002\/14651858.CD002947.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2985_CR30","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 2009;339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"key":"2985_CR31","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JJ Deeks","year":"2011","unstructured":"Deeks JJ, Higgins JP, Altman DG. Chapter 16: special topics in statistics. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. UK: The Cochrane Collaboration; 2011."},{"key":"2985_CR32","volume-title":"Chapter 8: assessing risk of bias in included studies. In: Higgins JP Green S, editors. Cochrane handbook or systematic reviews of interventions version 5.1.0","author":"JJ Deeks","year":"2011","unstructured":"Deeks JJ, Higgins JP, Altman DG. Chapter 8: assessing risk of bias in included studies. In: Higgins JP Green S, editors. Cochrane handbook or systematic reviews of interventions version 5.1.0. UK: The Cochrane Collaboration; 2011."},{"key":"2985_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.7150\/ijms.8.615","volume":"8","author":"AA Vishal","year":"2011","unstructured":"Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8:615\u201322.","journal-title":"Int J Med Sci"},{"key":"2985_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12906-017-2062-z","volume":"18","author":"A Haroyan","year":"2018","unstructured":"Haroyan A, Mukuchyan V, Mkrtchyan N, et al. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complement Altern Med. 2018;18:7. https:\/\/doi.org\/10.1186\/s12906-017-2062-z.","journal-title":"BMC Complement Altern Med"},{"key":"2985_CR35","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s10067-017-3603-z","volume":"36","author":"M Karimifar","year":"2017","unstructured":"Karimifar M, Soltani R, Hajhashemi V, et al. Evaluation of the effect of Elaeagnus angustifolia alone and combined with Boswellia thurifera compared with ibuprofen in patients with knee osteoarthritis: a randomized double-blind controlled clinical trial. Clin Rheumatol. 2017;36:1849\u201353. https:\/\/doi.org\/10.1007\/s10067-017-3603-z.","journal-title":"Clin Rheumatol"},{"key":"2985_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0394632015622215","volume":"29","author":"A Notarnicola","year":"2016","unstructured":"Notarnicola A, Maccagnano G, Moretti L, et al. Methylsulfonylmethane and boswellic acids versus glucosamine sulfate in the treatment of knee arthritis: randomized trial. Int J Immunopathol Pharmacol. 2016;29:140\u20136. https:\/\/doi.org\/10.1177\/0394632015622215.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2985_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s12325-011-0068-3","volume":"28","author":"A Notarnicola","year":"2011","unstructured":"Notarnicola A, Tafuri S, Fusaro L, et al. The \u201cMESACA\u201d study: methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis. Adv Ther. 2011;28:894\u2013906. https:\/\/doi.org\/10.1007\/s12325-011-0068-3.","journal-title":"Adv Ther"},{"issue":"5","key":"2985_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/01.rhu.0000138087.47382.6d","volume":"10","author":"A Chopra","year":"2004","unstructured":"Chopra A, Lavin P, Patwardhan B, Chitre D. A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees. J Clin Rheumatol. 2004;10(5):236\u201345.","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"2985_CR39","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/rheumatology\/kes414","volume":"52","author":"A Chopra","year":"2013","unstructured":"Chopra A, Saluja M, Tillu G, Sarmukkaddam S, Venugopalan A, Narsimulu G, Handa R, Sumantran V, Raut A, Bichile L, Joshi K, Patwardhan B. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence drug trial. Rheumatology (Oxford). 2013;52(8):1408\u201317. https:\/\/doi.org\/10.1093\/rheumatology\/kes414 Epub 2013 Jan 30.","journal-title":"Rheumatology (Oxford)"},{"key":"2985_CR40","unstructured":"Belcaro G, Dugall M, Luzzi R, Ledda A, Pellegrini L, Hu S, Ippolito E. Management of osteoarthritis (OA) with the pharma-standard supplement FlexiQule (Boswellia): a 12-week registry. Minerva Gastroenterol Dietol. 2015;22 [Epub ahead of print]."},{"issue":"24","key":"2985_CR41","first-page":"5198","volume":"20","author":"G Bolognesi","year":"2016","unstructured":"Bolognesi G, Belcaro G, Feragalli B, Cornelli U, Cotellese R, Hu S, Dugall M. Movardol\u00ae (N-acetylglucosamine, Boswellia serrata, ginger) supplementation in the management of knee osteoarthritis: preliminary results from a 6-month registry study. Eur Rev Med Pharmacol Sci. 2016;20(24):5198\u2013204.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2985_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/107628002761574635","volume":"12","author":"FA Badria","year":"2002","unstructured":"Badria FA, et al. Boswellia\u2013Curcumin Preparation for Treating Knee Osteoarthritis: A Clinical Evaluation. Alter and Comple Therap. 2002;12:341\u20138.","journal-title":"Alter and Comple Therap"},{"key":"2985_CR43","volume-title":"Cochrane handbook for systematic reviews of interventions. Chapter 14","author":"Y Loke","year":"2011","unstructured":"Loke Y, Price D, Herxheimer A. Chapter 14: adverse effects. In: JPT H, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chapter 14. Chichester: Wiley; 2011."},{"key":"2985_CR44","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","volume":"141","author":"JP Ioannidis","year":"2004","unstructured":"Ioannidis JP, Evans SJ, G\u00f8tzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781\u20138.","journal-title":"Ann Intern Med"},{"key":"2985_CR45","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JJ Deeks","year":"2011","unstructured":"Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analyzing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. UK: The Cochrane Collaboration; 2011."}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-020-02985-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-020-02985-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-020-02985-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T19:10:11Z","timestamp":1626462611000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-020-02985-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2985"],"URL":"https:\/\/doi.org\/10.1186\/s12906-020-02985-6","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]},"assertion":[{"value":"3 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}